UK

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

5 January 2020

OHE presents an overview on the use of cost-effectiveness thresholds (CETs) in a number of selected countries in their decision-making process for health technology assessments (HTAs).…

Indication-Based Pricing (IBP) Consultation Report

1 April 2020

Although the science underlying drug development has evolved, there has been little change in how we pay for them. As more and more medicines come to…

Anchoring Latent Scale Values for the EQ-5D-Y at 0 = Dead

1 January 2020

To date there have been no value sets to support the use of the EQ-5D-Y in cost-utility analysis. Discrete choice experiments (DCEs) can be used to…

HTA and Payment Mechanisms for New Drugs to Tackle AMR

1 September 2019

Antimicrobial resistance (AMR) is a growing public health threat, limiting the ability of health care systems to prevent and treat infections and save lives. In parallel,…

Valuing EQ-5D-Y Health States Using a Discrete Choice Experiment: Do Adult and Adolescent Preferences Differ?

7 January 2019

This Research Paper describes a study examining adolescent and adult responses to a discrete choice experiment (DCE) containing EQ-5D-Y health states in order to determine whether…

The Case of Risperidone: Assessing the Life-cycle Value of Second-Generation Antipsychotics in Sweden and the UK

1 July 2019

The present work aims to assess the life-cycle value of innovative medicines based on the example of Second-Generation Antipsychotics (SGA). Assessing the entire life-cycle of SGA,…

Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England

1 March 2019

Estimating a cost-effectiveness threshold reflecting the opportunity cost of adopting a new technology in a health system is not easy. This OHE research paper provides empirical…

Making Outcome-Based Payment a Reality in the NHS

2 January 2019

This report explores the feasibility of introducing one type of flexible payment mechanism – outcome-based payment (OBP) – for cancer medicines into the NHS in England. OBP could help to accelerate patient access to some new medicines and ensure close monitoring of real-world patient benefit.

Can a Strong Economic Case Be Made for Investing in the NHS?

1 January 2019

Debate about funding has highlighted the difficulty of persuading sceptics that the NHS is a good use of public finance. There is a widely held view…